StudyFinder
A Phase 2, Open-Label Study of Vobramitamab Duocarmazine in Participants with Metastatic Castration-Resistant Prostate Cancer and Other Solid Tumors (TAMARACK)
Recruiting
The study drug is an antibody-drug conjugate (ADC). An ADC is an antibody with an anti-cancer drug attached. The antibody portion of the ADC brings the anti-cancer drug specifically to the cancer cell, where it will attach to a protein on the outside of the cancer cell. When the ADC attaches to the cancer cell, the anti-cancer drug passes into the cancer cell and damages the cancer cell leading to the death of the cancer cell. Since the antibody portion contains a target that is specific to cancer cells, this helps keep the anticancer drug from hurting normal cells.
Male or Female
18 years and over
Inclusion Criteria:
• locally advanced or metastatic squamous cell carcinoma (SCC) of the anus, melanoma, head and neck squamous cell carcinoma (HNSCC), squamous non-small cell lung carcinoma (NSCLC), and small cell lung carcinoma (SCLC)
• received at least 1 prior line of systemic therapy for unresectable or metastatic disease and no more than 2 prior lines of cytotoxic chemotherapy
• participants with HNSCC or melanoma must have received prior PD-1 or PD-L1 inhibitor
• women must not be pregnant, planning to be pregnant, or breastfeeding
• see link to clinicaltrials.gov for complete inclusion and exclusion criteria
Exclusion Criteria:
• untreated, symptomatic central nervous system (CNS) metastasis
• prior stem cell, tissue, or solid organ transplant
• another cancer that was treated in the past two years
Cancer
Clinics and Surgery Center (CSC), anal cancer, head and neck squamous cell carcinoma, HNSCC, melanoma, SCC, squamous cell carcinoma
Emmanuel Antonarakis - anton401@umn.edu
Manish Patel
SITE00001784
See this study on ClinicalTrials.gov